NCT00017199View on ClinicalTrials.gov

PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

April 30, 2001

Study Completion Date

May 31, 2007

Conditions
Gastrointestinal Carcinoid TumorIslet Cell Tumor
Interventions
DRUG

bortezomib

Trial Locations (2)

60637-1470

University of Chicago Cancer Research Center, Chicago

43210-1240

Arthur G. James Cancer Hospital - Ohio State University, Columbus

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Ohio State University Comprehensive Cancer Center

OTHER

NCT00017199 - PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter